5 Science Park
395 Winchester Avenue
New Haven, CT 06511
United States
203 535 1456
https://www.arvinas.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 445
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. John G. Houston Ph.D. | Chairperson, CEO & President | 1.08M | N/D | 1960 |
Dr. Ian Taylor Ph.D. | Chief Scientific Officer | 692k | 1.25M | 1963 |
Dr. Randy Teel Ph.D. | Interim CFO & Treasurer | N/D | N/D | 1980 |
Mr. David K. Loomis M.B.A. | VP, Principal Accounting Officer & Chief Accounting Officer | N/D | N/D | 1974 |
Mr. Jeff Boyle | Vice President of Investor Relations | N/D | N/D | N/D |
Mr. Jared M. Freedberg J.D. | General Counsel & Corporate Secretary | N/D | N/D | 1969 |
Mr. Steve Weiss | Senior VP & Chief Human Resources Officer | N/D | N/D | 1970 |
Dr. John A. Grosso Ph.D. | Senior Vice President of R&D Technical Operations | N/D | N/D | 1957 |
Ms. Angela M. Cacace Ph.D. | Senior Vice President of Neuroscience & Platform Biology | N/D | N/D | 1968 |
Mr. John P. Northcott | Chief Commercial Officer | N/D | N/D | 1978 |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
La calificación ISS Governance QuickScore de Arvinas, Inc. a partir del 1 de marzo de 2024 es 8. Las puntuaciones principales son Auditoría: 4; Junta: 8; Derechos del accionista: 8; Compensación: 8.